Processa Pharmaceuticals Inc (NASDAQ: PCSA) is -70.58% lower on its value in year-to-date trading and has touched a low of $0.23 and a high of $3.10 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The PCSA stock was last observed hovering at around $0.26 in the last trading session, with the day’s loss setting it 0.0%.
Currently trading at $0.26, the stock is -29.74% and -46.40% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.55 million and changing -1.89% at the moment leaves the stock -76.31% off its SMA200. PCSA registered -91.07% loss for a year compared to 6-month loss of -79.37%. The firm has a 50-day simple moving average (SMA 50) of $0.48516 and a 200-day simple moving average (SMA200) of $1.09742.
The stock witnessed a -42.36% gain in the last 1 month and extending the period to 3 months gives it a -69.91%, and is -16.80% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 28.46% over the week and 20.32% over the month.
Processa Pharmaceuticals Inc (PCSA) has around 10 employees, a market worth around $1.37M and $0.00M in sales. Distance from 52-week low is 15.46% and -91.61% from its 52-week high. The company has generated returns on investments over the last 12 months (-698.44%).
The EPS is expected to grow by 75.19% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
9.0 institutions hold shares in Processa Pharmaceuticals Inc (PCSA), with institutional investors hold 1.98% of the company’s shares. The shares outstanding are 5.27M, and float is at 4.67M with Short Float at 1.95%. Institutions hold 1.88% of the Float.
Processa Pharmaceuticals Inc (PCSA) Insider Activity
The most recent transaction is an insider purchase by Yorke Justin W, the company’s Director. SEC filings show that Yorke Justin W bought 12,400 shares of the company’s common stock on Jan 27 ’25 at a price of $0.80 per share for a total of $9889.0. Following the purchase, the insider now owns 12400.0 shares.
Processa Pharmaceuticals Inc disclosed in a document filed with the SEC on Jan 27 ’25 that Ng George K (Chief Executive Officer) bought a total of 87,200 shares of the company’s common stock. The trade occurred on Jan 27 ’25 and was made at $0.80 per share for $69542.0. Following the transaction, the insider now directly holds 87200.0 shares of the PCSA stock.
Still, SEC filings show that on Jan 27 ’25, Young David (Pres. Research & Development) acquired 124,500 shares at an average price of $0.80 for $99289.0. The insider now directly holds 205,405 shares of Processa Pharmaceuticals Inc (PCSA).
